Salman Punekar
NYU Langone Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Salman Punekar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07249372 · DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung CancerNYU Langone Health · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph1NCT05815173 · Ladarixin With Sotorasib in Advanced NSCLCNYU Langone Health · recruiting · Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation · principal investigator
- Ph2NCT05815186 · Ladarixin With Sotorasib in Advanced NSCLC - Phase IINYU Langone Health · withdrawn · Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation · principal investigator
- Ph2NCT05807048 · Daratumumab in STK11 Mutated NSCLCNYU Langone Health · completed · Non-small Cell Lung Cancer With STK11/LKB1 Mutation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:42 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.N Engl J Med · 202663 citationsRCR 31.5
- 10 citationsRCR 5.0
- Effect of Y virilin on male infertility.J Postgrad Med · 19979 citationsRCR 0.4
- Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.N Engl J Med · 2026